Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins

Why It Matters

Investors can capture growth in the obesity‑treatment wave without betting on individual drug winners, while Dexcom’s expanding addressable market promises durable revenue upside.

Key Takeaways

• GLP‑1 users adopt CGM devices faster than non‑users
• Over nine million U.S. patients eligible for coverage lack CGM usage
• Dexcom’s Stelo OTC CGM expands reach to non‑insulin patients
• Third‑party manufacturers integrate Dexcom’s platform, creating network effects
• CGM market remains under‑penetrated, offering long‑term growth upside

Pulse Analysis

The surge in GLP‑1 weight‑loss drugs such as Ozempic and Wegovy has reshaped the diabetes landscape. As physicians prescribe these agents, many patients are newly diagnosed with diabetes or pre‑diabetes, creating a spill‑over demand for continuous glucose monitoring. Studies show CGM usage climbs faster among GLP‑1 recipients, turning what some saw as a threat into a catalyst for device makers.

Dexcom’s core CGM business has already captured a sizable share of a market that remains far from saturated. The company estimates more than nine million U.S. patients eligible for third‑party coverage still lack a CGM, underscoring a multi‑billion‑dollar upside. The recent launch of Stelo, an over‑the‑counter CGM approved for non‑insulin and pre‑diabetic users, broadens the addressable base beyond traditional Type 1 and insulin‑dependent Type 2 patients, accelerating adoption and revenue diversification.

Beyond product innovation, Dexcom benefits from a robust ecosystem effect. Numerous insulin‑pump and pen manufacturers have built devices that sync with Dexcom’s sensors, creating a virtuous cycle: a larger installed base attracts more partners, which in turn draws additional patients into the Dexcom network. This moat, combined with the under‑penetrated market and favorable regulatory trends, positions Dexcom for sustained double‑digit growth, making it a compelling play for investors seeking exposure to the obesity‑treatment boom without the volatility of drug development.